Condensed Consolidated Statements of Operations (unaudited) - USD ($) shares in Thousands, $ in Thousands	3 Months Ended
	Mar. 31, 2022	Mar. 31, 2021
Operating expenses:
Research and development	$ 10,945	$ 4,817
General and administrative	4,421	2,635
Total operating expenses	15,366	7,452
Operating loss	(15,366)	(7,452)
Other income:
Interest income, net	23	17
Total other income	23	17
Net loss	(15,343)	(7,435)
Accretion of redeemable convertible preferred stock to redemption value	0	(95,016)
Net loss attributable to common stockholders	(15,343)	(102,451)
Net loss attributable to common stockholders	$ (15,343)	$ (102,451)
Net loss per share attributable to common stockholders, basic and diluted
Net (loss) per share attributable to common stockholders, basic (usd per share)	$ (0.56)	$ (83.36)
Net (loss) per share attributable to common stockholders, diluted (usd per share)	$ (0.56)	$ (83.36)
Weighted-average common shares outstanding, basic and diluted
Weighted average common shares outstanding, basic (shares)	27,393	1,229
Weighted average common shares outstanding, diluted (shares)	27,393	1,229